Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Issue 5 (16th November 2017)

• Record Type: Journal Article
• Authors: Pontali, Emanuele; Sotgiu, Giovanni; Tiberi, Simon; D'Ambrosio, Lia; Centis, Rosella; Migliori, Giovanni B.
• Is Part Of: European respiratory journal. Volume 50:Issue 5(2017)
• Publication Date: 2017-11-16
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01462-2017
• Languages: English
• ISSNs: 0903-1936

Abstract

The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18]. Bedaquiline is well tolerated: evidence indicates a minority of patients discontinue use due to QT extension http://ow.ly/9NRT30fNv4y